SEOVF (Sernova Biotherapeutics) Net Income From Continuing Operations : $-20.34 Mil (TTM As of Jan. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sernova Biotherapeutics's net income from continuing operations for the three months ended in Jan. 2025 was $-3.96 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jan. 2025 was $-20.34 Mil.

Sernova Biotherapeutics Net Income From Continuing Operations Historical Data

The historical data trend for Sernova Biotherapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Net Income From Continuing Operations Chart

Sernova Biotherapeutics Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-4.03

-5.60

-17.84

-28.44

-23.40

Sernova Biotherapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-7.26	-7.27	-5.50	-3.61	-3.96

Sernova Biotherapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.34 Mil.

Sernova Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

PSH0:Germany SVA:Canada

Address

700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.